Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of “Moderate Buy” from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has received an average recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have assigned a buy rating and three have given a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $35.1429.

DYN has been the subject of several analyst reports. Tudor Pickering set a $23.00 price objective on Dyne Therapeutics in a report on Tuesday, December 9th. Raymond James Financial reissued a “strong-buy” rating and issued a $40.00 price objective on shares of Dyne Therapeutics in a research report on Monday, December 8th. Morgan Stanley dropped their target price on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. TD Cowen reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, December 8th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th.

Dyne Therapeutics Stock Down 0.1%

Shares of Dyne Therapeutics stock opened at $17.85 on Wednesday. The firm’s 50 day moving average price is $16.99 and its 200-day moving average price is $17.54. The company has a quick ratio of 22.25, a current ratio of 22.25 and a debt-to-equity ratio of 0.15. Dyne Therapeutics has a 52-week low of $6.36 and a 52-week high of $25.00. The company has a market cap of $2.95 billion, a P/E ratio of -5.04 and a beta of 1.34.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). On average, sell-side analysts predict that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, Director Brian S. Posner acquired 3,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The stock was purchased at an average cost of $15.06 per share, with a total value of $45,180.00. Following the transaction, the director directly owned 11,500 shares of the company’s stock, valued at $173,190. This trade represents a 35.29% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 20.77% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Darwin Wealth Management LLC lifted its stake in shares of Dyne Therapeutics by 0.5% during the third quarter. Darwin Wealth Management LLC now owns 173,517 shares of the company’s stock worth $2,195,000 after buying an additional 861 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after acquiring an additional 955 shares during the period. Creative Planning raised its stake in Dyne Therapeutics by 6.8% in the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after acquiring an additional 986 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after acquiring an additional 1,109 shares during the last quarter. Finally, Caxton Associates LLP lifted its position in Dyne Therapeutics by 10.9% during the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after acquiring an additional 1,627 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.